Immune checkpoint inhibitors revolutionized cancer care. They cause immune-related adverse events. ICI-induced type 1 diabetes is rare but serious. Patients need lifelong insulin. Doctors need risk factors for screening. In a study published in the Diabetes and Metabolism Journal, the researchers studied 6,956 patients from 2017-2023. ICI-T1DM diagnosis required insulin dependence and C-peptide <1.0 ng/mL. They found 32 cases (0.46%). Median onset was 41 weeks.
High-Risk Groups Need Close Monitoring
Pre-existing diabetes raised risk most. Hazard ratio reached 2.352 with 95% CI 1.140-4.854. Combination anti-PD-1/PD-L1 plus anti-CTLA-4 therapy tripled risk. HR was 3.666 with CI 1.224-10.979. Treatment over 12 weeks increased risk 4.8-fold. HR hit 4.789 with CI 1.806-12.701. Thyroid dysfunction also predicted diabetes. HR was 4.027 with CI 1.847-8.779.
Paradoxical Survival Benefit Observed
ICI-T1DM patients showed better survival. Hazard ratio was 0.224 with CI 0.093-0.539. Thyroid dysfunction linked to improved outcomes too. HR was 0.616 with CI 0.566-0.670. These immune-related adverse events may signal stronger immune activation against tumors.
Screening Protocols Must Change
Endocrinologists need urgent fasting glucose checks before ICI start. High-risk patients require weekly monitoring first 3 months. Combination therapy patients need C-peptide testing if glucose rises. Pre-diabetic patients should discuss ICI risks thoroughly. Thyroid function guides screening intensity too.
Management Saves Pancreas Function Early
Aggressive insulin initiation prevents DKA. Patient education prevents ER visits. Glucagon emergency kits go home with new cases. Serial C-peptide tracks residual beta cell function. Multidisciplinary tumor-endocrine teams coordinate care. Survival benefit supports continuing ICI despite diabetes onset.